Zenpep approved for exocrine pancreatic insufficiency (EPI) - MPR

Links shared publicly online about this topic.

  • 1,783
    total visits

Zenpep approved for exocrine pancreatic insufficiency (EPI) - MPR

empr.com

The FDA has approved Zenpep (pancrelipase delayed-release capsules, from Eurand N.V.), a pancreatic enzyme product (PEP) for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) or other conditions.

View full resource at empr.com

Tags: Pancreatic Disease, Cystic Fibrosis, FDA, News

  • Share

Most Recently Shared on August 31, 2009 at 8:35 pm By:

eMPR MPR

MPR News: Zenpep approved for exocrine pancreatic insufficiency (EPI): The FDA has approved Zenpep (pan.. http://bit.ly/45RlgT

3 years ago...

FDA clears Eurand's pancreatic enzyme drug Zenpep - Related Stories - AAP SmartBrief

smartbrief.com — “Eurand in Amsterdam gained FDA approval for its lead product, pancreatic enzyme drug Zenpep, for children age 1 and older as well as adults. The treatment, which is indicated for exocrine pancreatic insufficiency, will be available in four dosages in the U.S. next quarter. <a href='/servlet/aaRedireView full resource at smartbrief.com

  • View Related
  • Share

Most Recently Shared on September 1, 2009 at 3:02 am By:

Eurand Granted FDA Approval for Zenpep

drugs.com — “Zenpep (pancrelipase) is used to treat exocrine pancreatic insufficiency. Includes Zenpep side effects, interactions and indications.View full resource at drugs.com

  • View Related
  • Share

Most Recently Shared on August 29, 2009 at 7:33 pm By:

Advertisement